Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Cash from Operations (2023 - 2025)

Historic Cash from Operations for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to -$19.2 million.

  • Artiva Biotherapeutics' Cash from Operations fell 6536.9% to -$19.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$76.7 million, marking a year-over-year decrease of 5017.53%. This contributed to the annual value of -$55.0 million for FY2024, which is 1602.78% down from last year.
  • Per Artiva Biotherapeutics' latest filing, its Cash from Operations stood at -$19.2 million for Q3 2025, which was down 6536.9% from -$23.0 million recorded in Q2 2025.
  • Over the past 5 years, Artiva Biotherapeutics' Cash from Operations peaked at -$10.7 million during Q4 2023, and registered a low of -$23.0 million during Q2 2025.
  • For the 3-year period, Artiva Biotherapeutics' Cash from Operations averaged around -$15.4 million, with its median value being -$14.6 million (2024).
  • Its Cash from Operations has fluctuated over the past 5 years, first crashed by 802.94% in 2024, then tumbled by 6794.3% in 2025.
  • Quarter analysis of 3 years shows Artiva Biotherapeutics' Cash from Operations stood at -$10.7 million in 2023, then tumbled by 37.24% to -$14.6 million in 2024, then plummeted by 31.06% to -$19.2 million in 2025.
  • Its Cash from Operations was -$19.2 million in Q3 2025, compared to -$23.0 million in Q2 2025 and -$19.8 million in Q1 2025.